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ABSTRACT
The objective of this study was to describe the clinical characteristics of syndromic neonatal
diabetes in a family with a GATA6 mutation. A girl, currently aged 12 years 3 months, was born with
intrauterine growth retardation: weight 1600 g (–4.3 SDS) at term. After birth, foramen ovale and
patent ductus arteriosus (PDA) were diagnosed by echocardiography. Diabetes was diagnosed on
the 9th day after birth. Exocrine pancreatic insufﬁciency was clinically diagnosed at about 2 years
of age and pancreatic agenesis was revealed later by magnetic resonance imaging. Her father had
undergone surgery during infancy for PDA and had developed insulin dependent diabetes at
12 years of age. Ultrasound revealed a thin pancreas with normal length and anatomical structure.
He has subclinical exocrine pancreatic insufﬁciency, low insulin needs and no late complications of
diabetes up to the age of 40 years. Sequencing of GATA6 identiﬁed a heterozygous splicing
mutation, 1136-2A>G, in the girl and her father. Testing of the paternal grandparents showed that
the mutation was likely to have arisen de novo in the father. Identiﬁcation of a GATA6 mutation
explains the cardiac anomalies and diabetes in this family. This case highlights the marked intra-
familial variability of both exocrine and endocrine pancreatic phenotypes in patients with GATA6
mutations.
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Introduction
Genome sequencing technologies have helped to estab-
lish the etiology of diabetes mellitus (DM) in a small
group of pediatric patients presenting non-autoimmune
mechanisms of impaired insulin secretion. Some of them
are diagnosed in the neonatal period or during early
infancy. More than 20 gene mutations causing perma-
nent (PNDM) or transient (TNDM) neonatal diabetes mel-
litus have been identiﬁed [1].
The transcription factor GATA6 has been intensively
studied after the discovery of its role in the development
of the pancreas. GATA 4/5/6 subfamily presents primary
endodermal and mesodermal transcription factors,
expressed in the primitive endoderm and extra-embry-
onic tissues for supporting the growing epiblast [2–4]
and endodermal differentiation [5]. During organogene-
sis, GATA4/5/6 ensure the anatomical and functional
development of the pancreas, heart, blood vessels, hepa-
tobiliary system, urogenital tract, thyroid gland as well as
the brain [6,7]. GATA 4/6 have a leading role in the tran-
scriptional network hierarchy in pancreatic multipotent
progenitors arisen from the foregut endoderm [8,9].
In humans, GATA4 mutations were initially discovered
to cause familial congenital cardiac septal defects [10]
and have been found in some individuals from screened
series of patients with congenital non-syndromic cardiac
defects.[11–13] Further studies have shown that GATA4/
6 haploinsufﬁciency can also cause a combination of
pancreatic agenesis/hypoplasia, cardiac and hepatobili-
ary defects [14–16].
In this report we describe the clinical characteristics of
syndromic neonatal diabetes in a family, father and daugh-
ter, with a GATA6mutation. The genetic ﬁnding has already
been reported [16]. Here, the clinical features are described
in details and, especially, the marked phenotypic variability
between the two affected family members.
Subjects and methods
This study included two family members, father and
daughter, reportedly carrying a GATA6 mutation [16].
The girl patient, currently aged 12 years 3 months was
born with intrauterine growth retardation with weight
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1600 g (¡4.3 SDS), length 41 cm (¡4.8 SDS), following a
normal full-term pregnancy of a healthy mother and a
father diagnosed with type 1 diabetes at the age of
12 years.
Written informed consent to participate in this study
was obtained for both subjects. The study was approved
by the Ethics committee at the University Pediatric Hos-
pital–Soﬁa.
Genetic testing
Molecular genetic analysis was performed by screening
the coding sequence and »50 bp of ﬂanking sequence
of GATA6 using Sanger sequencing [16]. Sequencing
reactions were run on an ABI3730 capillary machine
(Applied Biosystems, Warrington, U.K.) and analysed
using Mutation Surveyor v3.98 (SoftGenetics, State Col-
lege, PA) (GATA6 nucleotide reference NM_005257.3).
Results and discussion
Clinical case
The ﬁrst ultrasound cardiac investigation of the girl
revealed foramen ovale, small patent ductus arteriosus
(PDA) and peripheral stenosis of both branches of the
pulmonary artery. At the age of 9 days, her condition
worsened with dehydration, weight loss up to 1200 g,
hyperglycemia of 30 mmol/L without ketonuria and
hyponatriemia 128 mmol/L (range 130–155). Intensive
insulin replacement therapy was started with diluted
short-acting human insulin at a daily dose of 0.05 U/kg
body weight (b.w.). Anti-GAD65, IAA and IA2 antibodies
were all negative. At the age of 20 days, E-peptide was
shown to be deﬁcient (73.1 pmol/L; range 174–
960 pmol/L).
The father was born with normal birth weight. He
underwent a cardiac operation in infancy for PDA and
developed diabetes at the age of 12 years. He has always
been with mild insulin requirements, treated with two
injections of mixed insulin at a daily dose 0.35 U/kg b.w.
He had no severe exocrine pancreatic insufﬁciency
proven by the following clinical evidence: no gastroin-
testinal problems in early childhood, normal physical
development with height of 178 cm, normal body mass
index, normal abdominal circumference, normal stools.
He has normal intellectual development, secondary edu-
cation and no late diabetes complications at the age of
40 years. In 2011, his examination revealed glycated
hemoglobin (HbA1c) 7.9%/62.84 mmol/mol (normal 4%–
6.2%/20.22–44.26 mmol/mol), normal hepatic function
and lipid metabolism. C-peptide was low: 88.2 pmol/L
(normal 196–960 pmol/L). Ultrasound investigation
revealed a hypoplastic thin pancreas but normal length
and anatomical structure. Fecal elastase measured at his
last visit was less than 15 mg/g feces (normal > 200 mg/
g), suggesting subclinical pancreatic insufﬁciency.
Clinical course
In the girl, the ligation of PDA was performed at 20
months of age because of clinically signiﬁcant signs of
large left to right shunting, marked left ventricular vol-
ume overload and congestive heart failure. After surgery,
the speciﬁc medical therapy was stopped and the car-
diac dimensions gradually normalized. During the ﬁrst
3 years of life, the main clinical issues were iron-deﬁcient
anemia, hypoproteinemia, mildly elevated transaminases
and subclinical biliary stasis, perhaps all attributable to
hepatic dysfunction and/or steatosis hepatitis due to
some degree of insulin deﬁciency and malnutrition
(Table 1).
Breast milk enriched in proteins and starch was given
in the ﬁrst few months after birth. Unusually large
amount of carbohydrates, up to 20–22 g/kg b.w. (normal
12–14 g/kg), was necessary to keep weight gain with a
corresponding insulin dose of 0.5 U/kg b.w. Follow-ups
of C-peptide were recorded at 3 months (79.6 pmol/L)
and 2 years (19.4 pmol/L). Clinical signs of exocrine pan-
creatic insufﬁciency appeared after 2 years of age:
abdominal distension, bulky stools 5–7 times daily with
steatorrhea with up to 50% of ingested fat. No weight
loss was seen and the insulin dose was stable (0.8–0.9 U/
kg b.w.). Unfortunately, we could not investigate fecal
Table 1. Laboratory signs of hepatic function.
Age ASATa U/L ALATb U/L GGTc U/L Alkaline phosphatase U/L
Total bilirubin
(mmol/L) (n < 17)
Direct bilirubin
(mmol/L) (n = 0–3.5)
3 months 76 (n < 61) 39 (n < 50) 316 (n = 4–163) 1626 (n = 124–341) 49.0 15.4
1.1 years 32 (n < 50) 42 (n < 36) 12 (5–31) 875 (108–317)
2 years 73 73 12 876
2.4 years 60 74 11 838
3 years 182 117 14 323
3.5 years 28 31 12 314
aAlanine aminotransferase.
bAspartate aminotransferase.
cGamma-glutamyl transpeptidase.
Note: n, normal (reference) value.
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elastase at the time. Ultrasound revealed initially a small
pancreas with 3.5 mm length. Replacement therapy simi-
lar to that of patients with cystic ﬁbrosis was initiated at
age of 2 years 2 months: 1000 lipase units/kg b.w. per
meal, Vitamin A 2000 U/d, Vitamin D 800 U/d and Vita-
min E 50 U/d. At the age of 4 years, magnetic resonance
imaging (MRI) was performed and conﬁrmed pancreatic
agenesis. Fecal elastase measured at her last visit was
less than 15 mg/g feces (normal > 200 mg/g).
Current status
The girl takes a normal traditional diet and receives three
to four injections of short-acting insulin analog for meals
and long-acting insulin analog at bedtime with a total
daily dose of 0.8 U/kg b.w. The dose of Creon is 75,000–
100,000 U daily. At the last examination, the plasma lev-
els of fat-soluble vitamins under daily supplemental ther-
apy were near the lower reference: Vitamin A, 0.24 mg/L
(0.3–0.8 mg/L); Vitamin E (tocopherol), 7.9 mg/L (5–
18 mg/L) and 25-OH-Vitamin D, 19.42 ng/mL (sufﬁciency
level 30–100 ng/mL).
At present (12 years 3 months of age), the girl’s height
is 151.5 cm (¡0.06 SDS), weight 37 kg (¡0.83 SDS)
(Figure 1). The expected ﬁnal height according to the
parent’s height is 162.5 § 5 cm.
She has normal pubertal (Tanner stage 3) and intellec-
tual development with good school performance and
normal physical activity. She maintains good glycemic
control with HbA1c 7%–8% (53.1–63.93 mol/mol). The
persisting small foramen ovale is followed by
cardiologists.
Figure 1. Growth chart of the girl since birth.
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Genetic testing
Agenesis of pancreas had not been suspected up to
2 years of age because of detectable C-peptide and no
clear signs of exocrine pancreatic insufﬁciency. A ﬁrst
series of DNA analyses excluded mutations in the
KCNJ11, ABCC8 and INS genes as well as biallelic muta-
tions in GCK. After MRI at 4 years of age, PDX1 and PTF1A
gene mutations were excluded as well.
Further analysis revealed a heterozygous GATA6 splic-
ing mutation, c.1136-2A>G. This mutation affects the
conserved splice acceptor site of intron 2 (c.1136-2A>G)
and is predicted to cause aberrant splicing (Figure 2).
Testing of parental samples revealed that the muta-
tion had been inherited from her father; therefore, very
likely to cause congenital heart defect as well as diabetes
in both patients. The mutation was not found in the DNA
sample from the paternal grandparents of the girl, indi-
cating that it has arisen de novo in the father.
Thus, in the family examined in this study, the autoso-
mal dominant transmission of a GATA6 mutation is asso-
ciated with a congenital heart defect (PDA) in the two
relatives, pancreatic agenesis and PNDM in the daughter
and pancreatic hypoplasia and juvenile-onset diabetes
in the father. In a cohort of 795 neonatal diabetes
patients, 24 (3%) have been reported to have GATA6
mutations, 21 of them with complete absence or marked
hypoplasia of the pancreas, including our patient [16].
The most frequent extra-pancreatic features among the
patients with GATA6 mutations are congenital heart
defects (83%), but additional extra-pancreatic features
are reported, too. McMillan et al. [17] report a case of
neonatal diabetes and pancreatic hypoplasia resulting
from a de novo mutation of the GATA6 gene and several
associated anomalies including truncus arteriosus, gall-
bladder agenesis, an inguinal hernia and protein-losing
enteropathy. This illustrates the variable phenotype
associated with mutations of this gene [17,18]. Some of
the patients have late onset diabetes, but others have
isolated cardiac defects only [16].
Our familial case of GATA6 haploinsufﬁciency presents
the main clinical characteristics of the syndrome: diabe-
tes and cardiac defect [15–21]. Among familial cases, var-
iable penetrance of the diabetes phenotype has been
reported regarding age of onset, severity of diabetes
Figure 2. Elecropherograms showing the presence of the GATA6 splicing mutation in the proband and her father.
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and exocrine insufﬁciency, whilst the cardiac phenotype
is highly penetrant [16,22,23]. The family described here
highlights the variable clinical presentation of the dia-
betic phenotype, with pancreatic agenesis and PNDM in
the proband and hypoplasia, juvenile onset diabetes
and subclinical exocrine insufﬁciency in the father. It is
of interest to discuss if the hypoplastic 3.5 mm pancreas
initially existed in the girl, being subjected to apoptosis
later on in the absence of GATA6 supportive transcrip-
tion factor. The same low levels of C-peptide and fecal
elastase in the daughter and in the father do not reﬂect
real pancreatic endocrine and exocrine functional capac-
ity in each patient. The proband is our ﬁrst case with
PNDM out of 4150 children with diabetes registered in
the Clinic of Diabetes at the University Pediatric Hospi-
tal – Soﬁa since 1970, including ﬁve children with TNDM.
Conclusions
Genetic analysis is important in patients with neonatal or
late onset syndromic diabetes. Identiﬁcation of the
genetic defect guides treatment and allows prognosis,
assessment of recurrence risk and prenatal diagnosis.
Identiﬁcation of a GATA6 mutation in the family
described here explains the cause of the syndromic neo-
natal and juvenile onset diabetes, although the mecha-
nism underlying the phenotypic variability of the disease
is still unknown. GATA 6 mutations could be suspected
at any age beyond infancy in diabetic patients with
inherited cardiac anomaly like in the father.
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